(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - ValiRx PLC on Tuesday said a requisition notice, which it received earlier in February, has been confirmed as invalid following legal advice. Read More
ValiRx PLC - Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics - Signs agreement with Dundee University's drug discovery unit to access research concerning novel therapeutic candidates. The agreement will be active for a period of five years, in which ValiRx may review research projects from the unit in areas aligned with the company's focus on cancer therapeutics. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
ValiRx PLC - life science company based near Birmingham, England, which is focused on early-stage cancer therapeutics and women's health - Says 3.2 million new shares have been subscribed for at 6 pence per share via a retail offer, raising GBP192,244. Also issues 499,998 new shares via a subscription. In total, raises GBP1.8 million via placing, subscription and retail offer of 30.0 million new shares. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - ValiRx PLC on Tuesday said that ValiSeek Ltd it has entered a deal to licence VAL401 with Ambrose Healthcare Ltd, a private UK specialist pharmaceutical company. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More
(Alliance News) - ValiRx PLC on Friday said it has signed a deal with StingRay Bio Ltd to investigate a series of drug candidates. Read More
(Alliance News) - ValiRx PLC on Friday said it had no unpublished information that was sensitive to its share price, as it rose significantly. Read More
(Alliance News) - ValiRx PLC on Thursday reported an increased half-year loss amid higher costs, as it continued to focus on building its science-focused portfolio. Read More
(Alliance News) - ValiRx PLC on Monday said its wholly-owned subsidiary, Inaphaea BioLabs Ltd, has entered into a collaborative services agreement with Agility Life Sciences Ltd. Read More
ValiRx PLC - Essex, England-based life science company focused on early-stage cancer therapeutics and women's health - Says subsidiary Inaphea BioLabs Ltd will partner with an unnamed UK-based biotechnology company on a phenotypic assay to investigate anti-cancer properties using patient-derived cells from Inaphea's biobank. Adds Inaphea has started internal studies on ValiRx assets s VAL301 and Cytolytix CLX001. "This defined work programme involves a multi-stage project and is expected to complete at the end of September 2023," ValiRx says. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Wednesday and not separately reported by Alliance News: Read More
ValiRx PLC - Essex, England-based life science company focused on early-stage cancer therapeutics and women's health - Says subsidiary Inaphaea Biolabs Ltd enters agreement with OncoBone Ltd. Says OncoBone clients will be able to access Inaphaea services. Notes Inaphaea is now confirmed as a cell-based assay supplier to OncoBone. Adds Inaphaea's services are now listed on scientist.com, a database website used by biotechnology and pharmaceutical companies. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
(Alliance News) - ValiRx PLC shares fell on Friday, after it ended its evaluation agreement with Hokkaido University to research a potential drug. Read More
(Alliance News) - Stock prices in London opened higher on Friday, taking their cue from Asian and US equities, while investors weighed recent interest rate decisions. Read More